Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
ADC Therapeutics SA Common Shares
(NY:
ADCT
)
3.535
-0.025 (-0.70%)
Streaming Delayed Price
Updated: 3:24 PM EST, Jan 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ADC Therapeutics SA Common Shares
< Previous
1
2
3
4
5
6
7
8
Next >
ADC Therapeutics Provides Business Updates
January 04, 2024
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA® in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
December 12, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Analyst Expectations for ADC Therapeutics's Future
↗
November 20, 2023
Via
Benzinga
ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards
November 07, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
The Latest Analyst Ratings for ADC Therapeutics
↗
September 12, 2023
Via
Benzinga
A Preview Of ADC Therapeutics's Earnings
↗
August 07, 2023
Via
Benzinga
4 Analysts Have This to Say About ADC Therapeutics
↗
July 25, 2023
Via
Benzinga
ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 07, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Why BEST Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
↗
November 06, 2023
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares surged 358% to $134.37 in pre-market trading after gaining 100% on Friday. The company’s stock began trading on Friday following merger...
Via
Benzinga
ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
November 06, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting
November 02, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023
October 24, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics to Participate in September Investor Conferences
September 05, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023)
August 30, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 10, 2023
↗
August 10, 2023
Via
Benzinga
ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 08, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023
August 01, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
↗
July 25, 2023
On Tuesday, 56 companies set new 52-week lows.
Via
Benzinga
Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
July 24, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
↗
July 24, 2023
On Monday morning, 70 companies achieved new lows for the year.
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
↗
July 21, 2023
On Friday, 54 companies hit new 52-week lows.
Via
Benzinga
ADC Therapeutics Pulls Plug On Mid-Stage Zynlonta Study In Untreated Lymphoma Patients After Patient Deaths
↗
July 21, 2023
ADC Therapeutics SA (NASDAQ: ADCT) announced that it plans to discontinue the Phase 2 LOTIS-9 trial evaluating Zynlonta (loncastuximab tesirine-lpyl) and rituximab in unfit or frail patients with...
Via
Benzinga
ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
July 20, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
Dow Rises More Than 200 Points; Adial Pharmaceuticals Shares Spike Higher
↗
July 11, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones surging more than 200 points on Tuesday. The Dow traded up 0.73% to 34,193.60 while the NASDAQ rose 0.25% to 13,720.16. The S&P...
Via
Benzinga
Why Siyata Mobile Shares Are Trading Lower By 21%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
July 11, 2023
Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares climbed 129.5% to $8.01 after gaining 9% on Monday.
Via
Benzinga
Crude Oil Rises 2%; ADC Therapeutics Shares Plummet
↗
July 11, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones surging over 100 points on Tuesday. The Dow traded up 0.41% to 34,082.47 while the NASDAQ rose 0.29% to 13,725.52. The S&P 500, also...
Via
Benzinga
Dow Jumps Over 100 Points; US Small Business Optimism Index Tops Estimates
↗
July 11, 2023
U.S. stocks traded higher this morning, with the Dow Jones gaining over 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.40% to 34,080.13 while the NASDAQ rose 0.23% to...
Via
Benzinga
ADC Therapeutics Stock Is Plunging Today - What's Going On?
↗
July 11, 2023
ADC Therapeutics SA (NASDAQ: ADCT) has voluntarily paused enrollment of new patients in the Phase 2 LOTIS-9 trial evaluating Zynlonta (loncastuximab tesirine-lpyl) and rituximab (Lonca-R) in unfit or...
Via
Benzinga
ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients
July 11, 2023
From
ADC Therapeutics SA
Via
GlobeNewswire
ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL
June 09, 2023
Data being presented at the EHA 2023 Hybrid Congress will also be highlighted in an encore oral presentation at 17-ICML
From
ADC Therapeutics SA
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
